الفهرس 
The effect of intravitreal Anti VEGF injection on choroidal thickness in diabetic macular edema
Table of contentsOnly 14 pages are availabe for public view
 |  | from | 111 |  |  |
| | | from | 111 | | |
Abstract
Objective: Diabetic macular edema is a common cause of diminution of vision in diabetic population worldwide. It is treated by photocoagulation, intravitreal steroids and intravitreal Anti-VEGF. The aim of this study is to determine the effect of Bevacizumab on choroid in Diabetic macular edema patients. Study design: A prospective interventional cohort study. Place and duration: This study was conducted in Ophthalmology department, Kasr Al-Ainy Hospital, Cairo University; from August 2014 till July 2016. Patients and methods: Forty eyes of 27 patients with clinically significant diabetic macular edema. All were subjected to full ophthalmological examination, baseline FFA, three IV Bevacizumab injections and EDI-OCT at baseline and one month after the third injection. Results: The pre injection subfoveal Choroidal thickness (CT) ranged from 145 to 465æm with average 320 ± 66 æm compared to post injection CT that ranged from 129 to 440 æm with average of 285.9 ± 71 æm and P value < 0.001. CT decreased significantly (P value < 0.001) also in all test points. More changes (decreased thickness) were observed in the responder groups (anatomical and functional) with p {u2013}value 0.041 and with p -value 0.023 respectively; the mean decrease was 49.68 æm in anatomical responders compared to 21.43 æm in non-responder group and 45.37 æm in functional responders group compared to 13.00 æm in non-responder group. Conclusion: Bevacizumab injections caused thinning of the choroid in patients with CSME with more thinning in the anatomical and functional responder patients